CCL18及其受体在女性恶性肿瘤中的研究现状

Research status of CCL18 and its receptor in female malignant tumors

在女性恶性肿瘤发生发展过程中,趋化因子CCL18及其作用受体起到了非常重要的作用。在乳腺癌中,CCL18主要作用于PITPNM3受体激活下游信号通路NF-κB以及PI3K/Akt/GSK3β/Snail促进肿瘤转移。在宫颈癌、卵巢癌中CCL18相关基因呈现高表达,并可以作为诊断的生物标志物。CCL18还可以作用于子宫内膜癌的ERα受体促进子宫内膜癌细胞的上皮间充质转化。CCL18及其受体在女性恶性肿瘤进展中起至关重要作用,但是在子宫内膜癌、宫颈癌及卵巢癌中的具体作用受体及调控机制仍不明确,这有待后续的进一步研究。

Chemokine CCL18 and its receptor play a very important role in the progression of female malignant tumors.In breast cancer,CCL18 mainly acts on the activation of downstream signaling pathway NF-κB and PI3K/Akt/GSK3β/Snail by PITPNM3 receptor,thus promotes tumor metastasis.CCL18 gene is highly expressed in cervical cancer and ovarian cancer,and can be used as a biomarker for diagnosis.CCL18 can also act on ERαreceptors of endometrial carcinoma promote the epithelial-mesenchymal transformation of endometrial cancer cells.CCL18 and its receptors play a critical role in the progression of female malignant tumors,but the specific receptor and regulatory mechanism of CCL18 in endometrial cancer,cervical cancer and ovarian cancer are still unclear,which needs further study in the future.